Study S000575

GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)Informed Consent Form (PDF)

Registration

Registration: NCT04779697
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 96
Start: 2021-02-01
Primary completion: 2024-11-19
Lead sponsor: Yale University
Conditions: Obesity
Interventions: DRUG:GLP-1 analogue - semaglutide; OTHER:Placebo
Results posted: TRUE
Secondary identifiers: NIH:2R01DK099039-06

Registered primary outcomes

Change in Craving Score [Average change in avg FCI craving score from week 0 to end of treatment (week 12) computed as avg FCI score at week 12 - avg FCI score at Week 0.]
Change in Hunger Score [Average change in hunger VAS rating from week 0 and end of study week 12 (week 12 VAS - Week 0 VAS)]
Change in Food Intake [Change in FST total calorie energy density (totalcalED)from FST at week 0 and FST during treatment at week 12 (week 12 FST - Week 0 FST totalcalED change)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.